WuXi Biologics (Cayman) Gestione

Gestione criteri di controllo 2/4

WuXi Biologics (Cayman) Il CEO è Chris Chen, nominato in Jan2016, e ha un mandato di 8.83 anni. la retribuzione annua totale è CN¥ 96.91M, composta da 4.1% di stipendio e 95.9% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.35% delle azioni della società, per un valore di $ 26.80M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.6 anni e 7.2 anni.

Informazioni chiave

Chris Chen

Amministratore delegato

CN¥96.9m

Compenso totale

Percentuale dello stipendio del CEO	4.1%
Mandato del CEO	8.8yrs
Proprietà del CEO	0.4%
Durata media del management	2.6yrs
Durata media del Consiglio di amministrazione	7.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Chris Chen rispetto agli utili di WuXi Biologics (Cayman)?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	CN¥3b
Mar 31 2024	n/a	n/a	CN¥3b
Dec 31 2023	CN¥97m	CN¥4m	CN¥3b
Sep 30 2023	n/a	n/a	CN¥4b
Jun 30 2023	n/a	n/a	CN¥4b
Mar 31 2023	n/a	n/a	CN¥4b
Dec 31 2022	CN¥79m	CN¥3m	CN¥4b
Sep 30 2022	n/a	n/a	CN¥4b
Jun 30 2022	n/a	n/a	CN¥4b
Mar 31 2022	n/a	n/a	CN¥4b
Dec 31 2021	CN¥51m	CN¥3m	CN¥3b
Sep 30 2021	n/a	n/a	CN¥3b
Jun 30 2021	n/a	n/a	CN¥3b
Mar 31 2021	n/a	n/a	CN¥2b
Dec 31 2020	CN¥31m	CN¥3m	CN¥2b
Sep 30 2020	n/a	n/a	CN¥1b
Jun 30 2020	n/a	n/a	CN¥1b
Mar 31 2020	n/a	n/a	CN¥1b
Dec 31 2019	CN¥25m	CN¥3m	CN¥1b
Sep 30 2019	n/a	n/a	CN¥922m
Jun 30 2019	n/a	n/a	CN¥831m
Mar 31 2019	n/a	n/a	CN¥731m
Dec 31 2018	CN¥20m	CN¥2m	CN¥631m
Sep 30 2018	n/a	n/a	CN¥520m
Jun 30 2018	n/a	n/a	CN¥410m
Mar 31 2018	n/a	n/a	CN¥331m
Dec 31 2017	CN¥24m	CN¥2m	CN¥253m

Compensazione vs Mercato: La retribuzione totale di Chris ($USD 13.38M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 7.78M ).

Compensazione vs guadagni: La retribuzione di Chris è aumentata di oltre il 20%, mentre gli utili aziendali sono diminuiti di oltre il 20% nell'ultimo anno.

AMMINISTRATORE DELEGATO

Chris Chen (51 yo)

8.8yrs

Mandato

CN¥96,911,000

Compensazione

Dr. Zhisheng Chen, also known as Chris, Ph.D. has been the Chief Executive Officer & Executive Director at WuXi Biologics (Cayman) Inc. since January 01, 2016 and since February 27, 2014 respectively. Dr....

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Ge Li	Founder & Chairman	10.8yrs	Nessun dato	Nessun dato
Zhisheng Chen	CEO & Executive Director	8.8yrs	CN¥96.91m	0.35% $ 26.8m
Weichang Zhou	Honorary President of Global Biologics Development	9.6yrs	CN¥32.89m	0.013% $ 1.0m
Ming Tu	CFO & Executive VP	3yrs	Nessun dato	Nessun dato
Lihua Yu	COO & Senior VP	less than a year	Nessun dato	Nessun dato
Sherry Gu	Chief Technology Officer and Executive VP of Global Biologics Development Department	less than a year	Nessun dato	Nessun dato
Jijie Gu	Chief Scientific Officer & President of Global Biologics Research	no data	Nessun dato	Nessun dato
Lina Fan	Senior VP & Head of Investor Relations	less than a year	Nessun dato	Nessun dato
He Wang	Chief Compliance Officer	2.2yrs	Nessun dato	Nessun dato
Li Xiong	VP & Head of Global Human Resources	no data	Nessun dato	Nessun dato
Angus Scott Turner	Senior VP and Head of Global BD & Alliance Management	no data	Nessun dato	Nessun dato
Keqiang Shen	Chief Digital Officer	4.8yrs	Nessun dato	Nessun dato

2.6yrs

Durata media

56.5yo

Età media

Gestione esperta: Il team dirigenziale di WXIB.F è considerato esperto (durata media dell'incarico 2.6 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Ge Li	Founder & Chairman	10.8yrs	Nessun dato	Nessun dato
Zhisheng Chen	CEO & Executive Director	10.8yrs	CN¥96.91m	0.35% $ 26.8m
Weichang Zhou	Honorary President of Global Biologics Development	8.5yrs	CN¥32.89m	0.013% $ 1.0m
Jackson Tai	Independent Non-Executive Director	1.5yrs	CN¥710.00k	0.00063% $ 47.8k
James Larrick	Member of Scientific Advisory Board	6.8yrs	Nessun dato	Nessun dato
David D. Ho	Member of Scientific Advisory Board	6.8yrs	Nessun dato	Nessun dato
Wei-Shou Hu	Member of Scientific Advisory Board	6.8yrs	Nessun dato	Nessun dato
Ram Sasisekharan	Member of Scientific Advisory Board	6.8yrs	Nessun dato	Nessun dato
William Robert Keller	Independent Non-Executive Director	7.5yrs	CN¥906.00k	0.00053% $ 40.2k
Yanling Cao	Non-Executive Director	8.5yrs	Nessun dato	Nessun dato
Yibing Wu	Non-Executive Director	8.5yrs	Nessun dato	Nessun dato
Kenneth Walton Hitchner	Independent Non-Executive Director	4.4yrs	CN¥933.00k	0.0050% $ 375.9k

7.2yrs

Durata media

59.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di WXIB.F sono considerati esperti (durata media dell'incarico 7.2 anni).

WuXi Biologics (Cayman) Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

Wuxi Biologics (Cayman) Inc. Announces Executive Changes

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Ning Zhao, Non-Executive Director, Member of Remuneration Committee and Member of Environmental, Social and Governance Committee

Recent updates

WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of remaining 30% stake in WuXi Vaccines (Cayman) Inc. from Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718).

WuXi Reportedly Explores Sale of Pharma Units as US Restrictions Loom

WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI in 2,000L GMP Manufacturing

WuXi Biologics (Cayman) Inc. to Report First Half, 2024 Results on Aug 21, 2024

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P International 700

WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024

WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

WuXi Biologics Receives U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 424,841,177 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2023.

Wuxi Biologics Successfully Implements Fully Integrated Continuous Process with Breakthrough Productivity of 6 g/L/Day At Pilot Scale

WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality

Wuxi Biologics (Cayman) Inc. Announces Executive Changes

WuXi Biologics (Cayman) Inc. to Report First Half, 2023 Results on Aug 23, 2023

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Ning Zhao, Non-Executive Director, Member of Remuneration Committee and Member of Environmental, Social and Governance Committee

WuXi Biologics (Cayman) Inc. Announces Board and Board Committee Changes

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2022 Results on Mar 22, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Teh-Ming Walter Kwauk, Independent Non-Executive Director, the Chairman of the Audit Committee of the Company and A Member of the Nomination Committee of the Company

Wuxi Biologics (Cayman) Inc. Announces Appointments to Strategy Committee

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 425,926,547 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2022.

WuXi Biologics (Cayman) Inc. Receives Regulatory Approvals for Drug Substance and Drug Product Facilities from U.S. FDA and EMA

WuXi Biologics (Cayman) Inc. Appoints Weichang Zhou as Member of the Strategy Committee

WuXi Biologics (Cayman) Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2022

Wuxi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Ended December 31, 2021

WuXi Biologics Announces Completion of GMP Production At 24,000L Line of Its Drug Substance Facility MFG5

WuXi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2021

WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of Biologics manufacturing facilities in Hangzhou of Pfizer Investment Co. Ltd.

WuXi Biologics (Cayman) Inc. (SEHK:2269) agreed to acquire a 90% stake in CMAB Biopharma Inc. from CBC Group.

WuXi Biologics (Cayman) Inc. (SEHK:2269) entered into an equity agreement to acquire Biologics manufacturing facilities in Hangzhou of Pfizer Investment Co. Ltd.

Exelixis, Inc. Enters into License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline

Wuxi Biologics (Cayman) Inc. Receives Remote Pre-Approval Inspection by European Medicines Agency on MFG4 Facility

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2020 Results on Mar 23, 2021

Antengene Corporation Limited Announces Collaboration with WuXi Biologics and WuXi STA to Advance Antibody-Drug Conjugate Candidate into Clinical-stage

Oxford BioTherapeutics Ltd Designates Second Bispecific Antibody Program Leveraging Wuxi Biologics’ Wuxibody® Platform

Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics’ WuXiBody® Platform

WuXi Biologics Receives GMP Certification from Brazil's ANVISA

WuXi Biologics (Cayman) Inc. (SEHK:2269) agreed into an Asset Purchase Agreement to acquire Drug Substance Facility in Wuppertal from Bayer Aktiengesellschaft (XTRA:BAYN) for € 110 million.

Arcus Biosciences, Inc. Expands Strategic Relationship with WuXi Biologics to Develop a Best-in-Class anti-CD39 Antibody for the Treatment of Cancer

AC Immune and WuXi Biologics Strengthen Strategic Partnership to Accelerate AC Immune’s Anti-TDP-43 Antibodies into Clinical Development

WuXi Biologics and AB2 Bio Ltd. Announces Collaboration to Accelerate Commercial-Scale Manufacturing of Tadekinig alfa

Antengene Announces Collaboration with WuXi Biologics to Advance the Development of Innovative Oncology Medicines

WuXi Biologics (Cayman) Inc. has completed a Follow-on Equity Offering in the amount of HKD 6.165 billion.

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media